Home > Insider Trading > Filing (0001127602-10-006155)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1097264	Allos Therapeutics Inc	ALTH	Pharmaceutical Preparations (2834)	541655029

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1202770	V James Caruso	11080 Circlepoint Road Suite 200 Westminster CO 80020	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-02-22	58,254	$0.00	147,127	No	4	A	Direct
Common Stock	Disposition	2010-02-23	5,968	$7.44	141,159	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Acquisiton	2010-02-22	102,300	$7.56	102,300	$7.56

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
102,300	2011-02-22	2020-02-22	No	4	A	Direct

Footnotes

Represents shares of common stock subject to restricted stock units ("RSUs") awarded under the Company's 2008 Equity Incentive Plan (the "Plan"). The RSUs vest in a series of four (4) successive equal annual installments over the four (4)-year period measured from the Vesting Commencement Date, subject to Participant's Continuous Service through each such date.
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan under which Mr. Caruso sold a portion of his holdings for tax and estate planning purposes.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $7.37 to $7.53. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
Stock options vest according to the following schedule: Twelve forty-eighths of the total number of shares subject to this option shall vest twelve (12) months after the vesting commencement date and an additional one forty-eighths (1/48) of the total number of shares subject to the option become exercisable each one-month period thereafter, until all such shares are exercisable.